Seroba Life Sciences

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Artica Therapeutics focuses on biotechnological research and development aimed at creating innovative therapies for severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods to facilitate the rapid advancement of drug candidates. This approach enhances the efficiency of the drug discovery process, ultimately enabling healthcare professionals to provide effective treatments for patients suffering from these challenging conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, expanding its impact within the healthcare sector.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs specifically for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product lineup includes SH-111, a sterile injectable solution for treating T-cell leukemia in both pediatric and adult patients, and SH-105, another oncology drug. Through its offerings, Shorla Pharma seeks to make a significant impact on patient care and improve clinical outcomes in the oncology sector.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Palliare focuses on advancing smoke insufflation and evacuation technologies for various surgical procedures, including robotic, laparoscopic, endoluminal, and colorectal surgeries. The company offers products such as the EVA15 insufflator and a comprehensive smoke evacuation system. Palliare aims to enhance surgical workflows by integrating its technologies with existing systems, thereby safeguarding operating room staff from the hazards associated with surgical smoke and aerosolized viruses. Their mission is to become a leader in advanced insufflation technology, catering to the needs of minimally invasive surgical practices.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Apica Cardiovascular is a pre revenue medical device company commercializing a technology for access and closure of the heart’s apex and the peripheral vascular system. The underlying technology has applications in a number of medical procedures such as Transcatheter Heart Valves (TAVI), AAA, and LVAD implantation. The technology standardizes access and closure for large bore therapeutic devices without loss of blood via minimally invasive surgical or percutaneous access on the beating heart. The technology has progressed to the point where it has proven the initial concept in animal and cadaver models and is now moving toward initial clinical trials.

Biosensia Ltd. is a company based in Dublin, Ireland, that specializes in point-of-care in-vitro diagnostics. It has developed RapiPlex, an innovative diagnostic platform designed to provide both quantitative and qualitative laboratory test results. RapiPlex consists of a disposable assay cartridge and a compact tabletop instrument, allowing for the transition of complex immunoassays from centralized laboratories to doctors' offices or patients' bedsides. This advancement supports near-patient care without sacrificing analytical performance. The platform is versatile, capable of analyzing various biological samples such as whole blood, plasma, serum, urine, saliva, and milk. Biosensia also focuses on applications in theranostics, veterinary testing, and food safety. The company was founded in 2000 and was previously known as NanoComms Ltd. Biosensia operates as a subsidiary of Kypha Inc. since 2018.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device that simultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries.

Provesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company’s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development. In addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target. Provesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company. Provesica has so far raised £4 million in finance to progress its lead programme through Phase 2 development.

Covagen is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases and cancer. The company specializes in creating bispecific FynomAbs by genetically fusing its proprietary Fynomer binding proteins to antibodies. This unique approach allows for the design of therapeutics with novel mechanisms of action and improved efficacy. Covagen's lead product, COVA322, is aimed at treating inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company was founded in 2007 as a spin-off from ETH Zurich and has established partnerships to enhance its drug development efforts, including a strategic collaboration with Mitsubishi Tanabe for the development of bispecific FynomAbs targeting specific disease-related pairs. A diverse group of investors supports Covagen’s initiatives, providing the necessary resources to advance its innovative therapeutic candidates.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.

Diabetica Ltd was established in September 2004 to commercialise discoveries at the Diabetes Research Group in the University of Ulster, under the leadership of scientific co-founders Prof Peter Flatt, Dr Neville McClenaghan and Prof Finbarr O'Harte.